araag2/HINT huggingface dataset:
Clinical trial NCT00561353 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: tmc435, placebo, peginterferon (pegifnα-2a), ribavirin
SMILES: [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria: - Documented chronic genotype 1 Hepatitis C infection - Able to comply
        with the protocol requirements and having good accessible veins - Amount of virus in the
        blood (HCV RNA) >= 10.000 IU/mL, at screening - Bodyweight as defined by a Quetelet Index
        (Body Mass Index [BMI]) between 18 and 32 kg/m², extremes included Exclusion Criteria: -
        Evidence of liver cirrhosis or decompensated liver disease or any other form of non-viral
        hepatitis - Participants receiving or having received treatment with polymerase inhibitor
        or protease inhibitor, or Standard of Care therapy with COPEGUS (ribavirin) and PEGASYS
        (peginterferon alpha-2a) for treatment for HCV during the 6 months before screening - Male
        participants with female partners of childbearing potential not agreeing to use a reliable
        birth control method, Female, except if postmenopausal for over 2 years, or
        posthysterectomy, or post-tubal ligation (without reversal operation) - History or evidence
        of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drug use,
        which would compromise the participant 's safety and/or compliance. A positive urine drug
        test at screening. Urine will be tested to check the current use of amphetamines, cocaine,
        and opioids (with the exclusion of methadone) - Participants having at least one lab
        toxicity that is found to be clinically significant - Participants co-infected with HIV, or
        Hepatitis A or B, or hepatitis B surface antigen, or active tuberculosis at screening,
        participants with prolonged QTc (>480 ms) value or any cardiac disease at screening, or any
        active clinically significant disease (e.g., cardiac dysfunction, cardio(myo)pathy, cardiac
        insufficiency), or medical history or physical examination findings during screening that,
        in the Investigator's opinion, would compromise the outcome of the trial - Participants
        having uncontrolled/unstable diabetes, epilepsy, a manifest psychiatric disease, non-stable
        methadone (or equivalent drug) use or participants having any other unstable disease,
        participants enrolled in another clinical trial within 90 days prior to screening
Clinical trial NCT00238238 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        -  Documentation of Disease

               -  Previously treated, histologically confirmed follicle center cell lymphoma, World
                  Health Organization (WHO) classification, grade 1, 2, or 3a

               -  Institutional flow cytometry or immunohistochemistry must confirm Cluster of
                  Differentiation 20 (CD20) antigen expression.

          -  Prior Treatment

               -  Patient must have been treated with rituximab either alone or in combination with
                  chemotherapy.

               -  Patient must have a time to progression of ≥ 6 months from last rituximab dose.

               -  No corticosteroids within two weeks prior to study, except for maintenance
                  therapy for a non-malignant disease. Maintenance therapy dose may not exceed 20
                  mg/day prednisone or equivalent.

               -  No prior radioimmunotherapy within 12 months of study entry.

          -  Age ≥ 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

          -  Measurable disease must be present either on physical examination or imaging studies.
             Non-measurable disease alone is not acceptable. Any tumor mass >1 cm is
             acceptable.Lesions that are considered non-measurable include the following:

               -  Bone lesions

               -  Ascites

               -  Pleural/pericardial effusion

               -  Lymphangitis cutis/pulmonis

               -  Bone marrow

          -  No known Central Nervous System (CNS) involvement by lymphoma.

          -  No known Human Immunodeficiency Virus (HIV) infection.

          -  Non-pregnant and non-nursing.

          -  Patients with a "currently active" second malignancy, other than non-melanoma skin
             cancers, are not eligible.

          -  Patients with a recent history (within 3 months of study entry) of Deep Vein
             Thrombosis/Pulmonary Embolism (DVT/PE) are not eligible.

          -  Required Initial Laboratory Values:

               -  Absolute Neutrophil Count (ANC) ≥ 1000/µL

               -  Platelet count ≥ 75,000/µL

               -  Creatinine < 1.5 x Upper Limit of Normal (ULN) unless attributed to lymphoma or
                  calculated clearance > 50 mL/min (patients on dialysis are not eligible)

               -  Total Bilirubin ≤ 2 x ULN unless attributed to lymphoma or Gilbert's disease
Clinical trial NCT00137826 (phase 2, status: completed)
Conditions: mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: erlotinib, bevacizumab
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Mesothelioma that has been previously treated with at least one chemotherapy regimen

          -  18 years of age or older

          -  Must at least be able to walk and capable of taking care of oneself although unable to
             carry out work activities

          -  Four or more weeks since last major surgery

          -  Four or more weeks since last radiation therapy

          -  Three or more weeks since last chemotherapy

          -  Life expectancy of 12 weeks or more

          -  Blood tests that show kidneys, liver and bone marrow to be working adequately

          -  Able to comply with study and/or follow-up procedures

        Exclusion Criteria:

          -  Prior exposure to Tarceva (OSI-774, erlotinib), trastuzumab, ZD1839 or C225

          -  Receiving anticoagulation medication other than low dose Coumadin

          -  Clinically significant heart disease such as uncontrolled hypertension, previous heart
             attack within past 12 months, uneven heartbeat, etc.

          -  History of central nervous system disease such as seizures not controlled with
             standard medical therapy, brain metastases or history of stroke

          -  Major surgery within 28 days of screening

          -  Daily treatment with aspirin or anti-inflammatory medications

          -  Pregnant or lactating (pertaining to women only)

          -  Serious or nonhealing wound, ulcer or bone fracture

          -  Difficulty swallowing

          -  A disease or disorder that interferes with ability to digest and absorb food

          -  History of coughing up more than 1/4 teaspoon of blood

          -  A medical condition that could make it unsafe for patient to participate in this study
Clinical trial NCT00683735 (phase 2/phase 3, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: sitagliptin, metformin, placebo, placebo
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2-diabetes mellitus

          -  BMI 25-35 kg/m2

          -  HbA1c 6.5%-9% (without OHA medication)

          -  HbA1c 6%-8.5% (OHA monotherapy with metformin or sulfonylurea)

          -  Patient understands the study-procedures

        Exclusion Criteria:

          -  Type 1-diabetes mellitus

          -  C-peptide < 0.7ng/mL (0.23 nmol/L)

          -  Patient has been taking oral anti-hyperglycemic agent (OHA) within the prior 12 weeks,
             except metformin or a sulfonylurea

          -  Patient has required insulin therapy within the past 12 weeks
Clinical trial NCT00085423 (phase 2, status: completed)
Conditions: melanoma (skin)
ICD codes: C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, D03.52
Drugs: cyclophosphamide, fludarabine phosphate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed melanoma

          -  Metastatic disease

          -  Measurable disease

          -  No history of brain metastases

          -  Over 18

          -  Karnofsky 60-100%

          -  Life expectancy At least 12 weeks

          -  Hematopoietic

          -  Absolute neutrophil count ≥ 1,000/mm^3

          -  Platelet count ≥ 75,000/mm^3

          -  Hemoglobin ≥ 8.5 g/dL

          -  aspartate aminotransferase ≤ 2 times upper limit of normal (ULN) (5 times ULN if liver
             metastases are present)

          -  Bilirubin ≤ 2 times ULN (except for patients with Gilbert's syndrome)

          -  Hepatitis B and C negative

          -  Creatinine ≤ 2.0 times ULN

          -  Creatinine clearance ≥ 50 mL/min

          -  Cardiovascular

          -  Ejection fraction ≥ 50%

          -  No evidence of congestive heart failure

          -  No symptoms of coronary artery disease

          -  No serious cardiac arrhythmias

          -  No myocardial infarction within the past 6 months

          -  Cardiac stress test negative or of low probability for patients > 40 years of age OR
             who have had prior myocardial infarction > 6 months ago

          -  Pulmonary Forced expiratory volume 1 ≥ 2.0 liters OR at least 75% of predicted for
             height and age

          -  Diffusing capacity of lung for carbon monoxide ≥ 60%

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

        Exclusion Criteria:

          -  No uncontrolled diabetes

          -  No history of autoimmune disease

          -  No active infection

          -  No other concurrent significant illness that would preclude study participation

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or
             non-invasive cancer (e.g., carcinoma in situ of the cervix, superficial bladder cancer
             without local recurrence, or carcinoma in situ of the breast)

          -  At least 4 weeks since prior immunotherapy and recovered

          -  No other concurrent anticancer biologic agents

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  No concurrent chemotherapy

          -  At least 4 weeks since prior steroid therapy

          -  No concurrent corticosteroids

          -  At least 4 weeks since prior radiotherapy and recovered

          -  No concurrent radiotherapy

          -  At least 4 weeks since prior surgery and recovered

          -  No concurrent immunosuppressive therapy
Clinical trial NCT01103583 (phase 2/phase 3, status: terminated)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: hydroxyurea
SMILES: NC(=O)NO
Reason stopped: 
    no efficacy (interim.analysis)
  
Eligibility criteria:

        Inclusion Criteria:

          -  sign written informed consent

          -  18 to 60 years of age inclusive

          -  diagnosis of PP-MS according to McDonald criteria

          -  EDSS score at screening of 2-7 inclusive

        Exclusion Criteria:

          -  hypersensitivity to hydroxyurea

          -  patients who were treated with immunosuppressive drugs or steroid three month before

          -  respiratory or urinary infections

          -  history or presence of malignancy

          -  pregnancy or lactation

          -  low compliance to the therapy
Clinical trial NCT00578097 (phase 2, status: terminated)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was terminated early due to poor recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  The subject has a diagnosis of idiopathic overactive bladder, without incontinence.

          -  The subject has ≥ 3 urgency episodes over the course of the 3 days immediately
             preceding the Baseline visit.

          -  The subject has ≥ 24 episodes of micturition over the course of the 3 days immediately
             preceding the Baseline visit.

        Exclusion Criteria:

          -  Bladder outlet obstruction (on urodynamic assessment).

          -  Post-Micturition Residual Volume > 150 ml (ultrasound assessment).

          -  Evidence of a urinary tract infection at Screening or Baseline in the study.

          -  Active or history of interstitial cystitis, malignancy of the bladder or urothelial
             tract, a carcinoma in situ (non malignant melanoma is allowed) bladder and/or kidney
             stones.
Clinical trial NCT00317694 (phase 2, status: completed)
Conditions: chronic kidney failure
ICD codes: N99.0, I13.0, I13.10, I13.11, I13.2
Drugs: fermagate, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects on active haemodialysis, aged 18 years or over.

          -  Written informed consent given.

          -  On a stable haemodialysis regimen (three times per week) for at least 3 months and be
             unlikely to change their dialysis prescription during the study period.

          -  On a stable dose of a phosphate binder for at least 1 month prior to screening.

          -  Willing to abstain from taking any phosphate binder or oral magnesium, aluminum or
             iron-containing products and preparations, other than the study medication.

          -  Willing to avoid any intentional changes in diet such as fasting, dieting or
             overeating.

          -  Willing to maintain their usual type and dose of Vitamin D supplementation.

        Exclusion Criteria:

          -  Participation in any other clinical trial using an investigational product or device
             within the previous 4 months.

          -  A significant history of alcohol, drug or solvent abuse in the opinion of the
             investigator.

          -  Any disease or condition, physical or psychological, which in the opinion of the
             investigator would compromise the safety of the subject or increase the likelihood of
             the subject being withdrawn.

          -  Clinically significant laboratory findings (for this subject population) in the
             opinion of the investigator.

          -  Any malignancy requiring treatment within 5 years of screening with the exception of
             basal cell carcinoma and Bowen's disease.

          -  A history of a motility disorder of the intestines, including, but not limited to,
             gastroparesis, ileus, pseudo-obstruction, megacolon, or mechanical obstruction.

          -  A significant illness in the 4 weeks before screening.

          -  Taking medication prescribed for seizures.

          -  A history of haemochromatosis.

          -  A history of high serum ferritin concentration of ≥ 1000ng/ml (excluding transient,
             treatment-induced ferritin elevation).

          -  A history of dysphagia or swallowing disorders that might limit the subject's ability
             to swallow study medication in the opinion of the investigator.

          -  Female subjects who are lactating or pregnant. Women of childbearing potential
             (pre-menopausal and not surgically sterilized) unless they are using a reliable
             contraceptive method, that is, barrier methods, hormones or intrauterine device.

          -  Current haemoglobin concentration of < 10.00 g/dL.

          -  Allergy to the IMP or its constituents.
Clinical trial NCT00718562 (phase 2, status: completed)
Conditions: gastrointestinal stromal tumors
ICD codes: C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, C49.A9
Drugs: amn107
SMILES: CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Documented disease progression during imatinib and sunitinib therapy OR intolerance to
             imatinib and/or sunitinib

          -  At least one measurable site of disease on CT/MRI scan

          -  PS≤2

          -  Normal organ, electrolyte, and bone marrow function

        Exclusion Criteria:

          -  Previous treatment with nilotinib or any other drug in this class or other targeted
             therapy

          -  Treatment with any cytotoxic and/or investigational drug ≤ 4 weeks prior to study
             entry

          -  Impaired cardiac function

          -  Use of coumarin derivatives (i.e. warfarin)

          -  Women who are pregnant or lactating

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00676663 (phase 2, status: completed)
Conditions: breast cancer, estrogen receptor-positive breast cancer, breast cancer, estrogen receptor-positive, er+ breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: entinostat, exemestane, placebo
SMILES: NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal female patients

          -  Histologically or cytologically confirmed estrogen receptor positive (ER+) breast
             cancer

          -  Relapsed or progressed on prior treatment with aromatase inhibitor (AI)

          -  Metastatic disease must be measurable

          -  Patients receiving palliative radiation at the non-target lesions must have a 2 week
             wash out period following completion of the treatment prior to enrollment

          -  Patient may have had one prior chemotherapy as part of first line therapy as long as
             it was received before initiation of prior AI

          -  Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 1

          -  Laboratory parameters: a)Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100.0 x 10^9/L; Absolute
             Neutrophil Count (ANC ≥) 1.5 x 10^9/L without the use of hematopoietic growth factors
             b)Creatinine less than 2.5 times the upper limit of normal for the institution
             c)Aspartate transaminase (AST) and alanine transaminase (ALT) less than 2.5 times the
             upper limit of normal for the institution

          -  Able to understand and give written informed consent and comply with study procedures

        Exclusion Criteria:

          -  Relapse on treatment with non-steroidal AI after less than 12 months for patients in
             the adjuvant setting

          -  Progressive disease after less than 3 months treatment with most recent AI for
             patients with metastatic disease

          -  Rapidly progressive, life-threatening metastases

          -  Any palliative radiotherapy to the measurable lesion

          -  Previous treatment with SNDX-275 or any other histone deacetylase (HDAC) inhibitor
             including valproic acid

          -  Allergy to benzamides or inactive components of the study drug

          -  A history of allergies to any active or inactive ingredients of exemestane

          -  Any concomitant medical condition that precludes adequate study treatment compliance

          -  Patient is currently enrolled in (or completed within 30 days before study drug
             administration) another investigational drug study

          -  Patient is currently receiving treatment with valproic acid, Zolinza (vorinostat) or
             any other HDAC inhibitor or deoxyribonucleic acid (DNA) methyltransferase inhibitor or
             any systemic anticancer treatment (with the exception of Lupron)
Clinical trial NCT01424930 (phase 2, status: completed)
Conditions: prostate neoplasms, prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: abiraterone, prednisone
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Adenocarcinoma of the prostate

          -  Metastatic disease documented by bone, computed tomography (CT) or magnetic resonance
             imaging (MRI) scan

          -  Surgical or medical castration with testosterone less than 50 ng/dL (< 2.0 nM)

          -  Prostate-specific antigen (PSA) or radiographic progression documented by assessments
             specified in study protocol

          -  Platelets >100,000/µl

          -  Hemoglobin >=9.0 g/dL

          -  Liver function tests (LFTs): Serum bilirubin < 1.5 x ULN; AST or ALT < 2.5 x ULN;
             Eastern Cooperative Oncology Group (ECOG) status score of <=2

        Exclusion Criteria:

          -  Small cell carcinoma of the prostate

          -  Known brain metastasis, chronic liver disease with elevated LFTs

          -  Prior cytotoxic chemotherapy for metastatic prostate cancer

          -  Treatment of prostate cancer within 30 days of Day 1 Cycle 1 with surgery, radiation,
             chemotherapy or immunotherapy

          -  Use of investigational drug within 30 days of Day 1 Cycle 1 or current enrollment in
             an investigational drug or device study

          -  Recent history of ischemic heart disease, Electrocardiogram (ECG) abnormalities or
             atrial fibrillation

          -  Active infection or other medical condition that would make prednisone
             (corticosteroid) use contraindicated

          -  Chronic medical condition requiring a higher dose of corticosteroid than prednisone 5
             mg twice daily